Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.

BMC Cancer · 2023 · PMC10108521 · PMID 37069542

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although not statistically significant, potentially due to limited patient counts, patients with KRAS G12C– positive cancer treated with 1L CIT showed a trend toward longer survival vs patients with KRAS WT cancer.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.